PL
JANX icon

Parkwood LLC’s Janux Therapeutics JANX Stock Holding History

Parkwood LLC’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,390
Closed -$477K – 108
2024
Q2 		$477K Buy
+11,390
New +$535K 0.06% 111
2023
Q1 		– Sell
-21,469
Closed -$283K – 169
2022
Q4 		$283K Sell
21,469
-11,883
-36% -$174K 0.04% 132
2022
Q3 		$452K Sell
33,352
-398
-1% -$5.32K 0.07% 118
2022
Q2 		$412K Buy
33,750
+5,492
+19% +$65K 0.07% 118
2022
Q1 		$405K Sell
28,258
-3,870
-12% -$63.3K 0.07% 105
2021
Q4 		$634K Buy
32,128
+11,351
+55% +$238K 0.11% 86
2021
Q3 		$449K Buy
+20,777
New +$598K 0.05% 104

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkwood LLC's JANX Position: Q3 2024 in Review

Parkwood LLC sold out of Janux Therapeutics (JANX) in Q3 2024, closing a stake of 11,390 shares — an estimated $477K sold.

Parkwood LLC first reported a position in JANX in Q3 2021 and held it in 7 quarters. The position peaked at $634K in Q4 2021. 160 funds tracked by Wall St. Rank hold JANX as of Q3 2024.

  • Parkwood LLC reported no remaining Janux Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Parkwood LLC sold 11,390 Janux Therapeutics shares in Q3 2024, an estimated $477K.
  • Parkwood LLC first reported a position in Janux Therapeutics in Q3 2021 and held it in 7 quarters.
  • Parkwood LLC's Janux Therapeutics position peaked at $634K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.